- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02105532
Transfusion in Gastrointestinal Bleeding (TRIGGER)
April 2, 2014 updated by: Dr Vipul Jairath
A Multi-centre, Feasibility, Cluster Randomised Controlled Trial Comparing Restrictive Versus Liberal Blood Transfusion Strategies in Adult Patients Admitted With Acute Upper Gastrointestinal Bleeding
Aim: To evaluate the feasibility and safety of a restrictive versus liberal red blood cell (RBC) transfusion policy in adult patients admitted with Acute Upper Gastrointestinal Bleeding (AUGIB) in order to inform the design of a definitive phase III randomised controlled trial.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Trial overview: TRIGGER is a pragmatic trial aiming to recruit adult patients admitted with all cause AUGIB (non-variceal and variceal).
The study will take place in six United Kingdon hospitals and they will be randomly allocated to a transfusion policy at the cluster level; three sites will be allocated to a restrictive transfusion policy and three to a liberal transfusion policy.
Given the challenges that will be involved in early recruitment and cross-speciality care, a feasibility study is essential to determine whether a sufficient proportion of eligible patients can be recruited into the trial and that clinicians can adhere to the allocated transfusion policy.
Recruitment will operate for 6 months in total.
The investigators will compare recruitment rate, protocol adherence, clinical characteristics of patients recruited, exposure to RBC transfusions and the difference in Hb concentrations between the restrictive and liberal transfusion policies.
The investigators will collect important clinical outcomes which the investigators anticipate being central to the phase III trial, including 28-day mortality, further bleeding rates and serious adverse events between the restrictive and liberal transfusion policies.
The investigators will also collect data to enable us to plan a health economic evaluation and quality of life assessment for the phase III trial.
Study Type
Interventional
Enrollment (Actual)
936
Phase
- Phase 2
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Oxford, United Kingdom
- NHSBT Clinical Studies Unit
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Adults aged 18 or over years presenting with AUGIB, defined by haematemesis or melaena.
Exclusion Criteria:
- Patients with whom the responsible clinician considers there is a need for immediate RBC transfusion prior to obtaining or regardless of the initial Hb result due to severity of bleeding.
- Existing hospital in-patients who develop AUGIB.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Restrictive Transfusion Policy
Participants allocated to this group will be eligible for transfusion once their Hb level is ≤ 8 g/dL after presentation to hospital.
The objective for the attending clinician is to maintain the Hb level between 8.1-10 g/dL for the duration of hospital stay.
|
Participants allocated to this group will be eligible for transfusion once their Hb level is ≤ 8 g/dL after presentation to hospital.
The objective for the attending clinician is to maintain the Hb level between 8.1-10 g/dL for the duration of hospital stay.
|
Active Comparator: Liberal Transfusion Policy
Participants allocated to this group will be eligible for transfusion once their Hb level is ≤ 10 g/dL after presentation to hospital.
The objective for the attending clinician is to maintain the Hb level between 10.1-12 g/dL for the duration of hospital stay.
|
Participants allocated to this group will be eligible for transfusion once their Hb level is ≤ 10 g/dL after presentation to hospital.
The objective for the attending clinician is to maintain the Hb level between 10.1-12 g/dL for the duration of hospital stay.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adherence to the study protocol
Time Frame: up to 28 days
|
Protocol adherence will be measured over time, to determine if adherence rates improve.
Adherence rates will also be compared between transfusion arms.
|
up to 28 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Further Bleeding
Time Frame: up to 28 days
|
Further bleeding up to Day 28: Further bleeding is a composite outcome that includes persistent bleeding (defined as any bleeding present at the end of the index endoscopy, regardless of whether endoscopic therapy was attempted or not), and recurrent bleeding.
Recurrent bleeding is only assessed in patients without persistent bleeding, and must be confirmed by the presence of high-risk stigmata of bleeding either endoscopically, radiologically, or surgically.
Recurrent bleeding should initially be suspected in the event of any combination of the following: fresh haematemesis, continuous melaena, or aspiration of fresh blood from a naso-gastric tube, with a pulse rate of >100 bpm, a fall in systolic blood pressure of >30mm Hg or a drop in Hb of >2g/dL in the preceding 24 hours.
Persistent bleeding and recurrent bleeding will also be assessed separately.
|
up to 28 days
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Red Blood Cell exposure in patients
Time Frame: up to 28 days
|
The difference in number of red blood cell units administered will be compared between the intervention groups up to discharge/death/Day 28 (whichever comes first).
|
up to 28 days
|
Selection bias
Time Frame: 6 months
|
Clinical characteristics of patients in the two transfusion policies
|
6 months
|
Difference in Hb concentration Between Restrictive and Liberal Groups
Time Frame: up to 28 days
|
The mean Hb values for patients will be compared between the treatment arms up to discharge/death/Day 28 (whichever comes first).
|
up to 28 days
|
Death
Time Frame: up to 28 days
|
All-cause mortality up to Day 28.
|
up to 28 days
|
Need for therapeutic intervention at the index endoscopy
Time Frame: up to 28 days
|
This includes any therapeutic modality performed for AUGIB at the index endoscopy.
|
up to 28 days
|
Need for surgery or radiological intervention to control bleeding
Time Frame: up to 28 days
|
up to 28 days
|
|
Proportion of patients experiencing the composite endpoint of thromboembolic and ischaemic events up to Day 28
Time Frame: up to 28 days
|
Includes myocardial infarction, stroke, pulmonary embolus, Deep Vein Thrombosis, acute kidney injury.
Each component will also be assessed individually.
See section 8.1.3
for a definition of ischaemic and thromboembolic events.
|
up to 28 days
|
Acute Transfusion reactions up to death/ discharge
Time Frame: up to 28 days
|
Defined as a reaction occurring at any time up to 24 hours following a transfusion of a blood component.
|
up to 28 days
|
Infections
Time Frame: up to 28 days
|
Any infection necessitating a prescription for the use of antibiotic treatment for a minimum of 5 days, provided the prescription is received before or on Day 28.
|
up to 28 days
|
Length of hospital stay
Time Frame: up to 28 days
|
up to 28 days
|
|
Health related quality of life at Day 28
Time Frame: 28 days
|
28 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Study Chair: Professor Michael F Murphy, NHS Blood and Transplant
- Study Director: Vipul Jairath, NHSBT and Translational Gastroenterology Unit, Oxford, UK.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Kahan BC, Jairath V. Outcome pre-specification requires sufficient detail to guard against outcome switching in clinical trials: a case study. Trials. 2018 May 2;19(1):265. doi: 10.1186/s13063-018-2654-z.
- Jairath V, Kahan BC, Gray A, Dore CJ, Mora A, James MW, Stanley AJ, Everett SM, Bailey AA, Dallal H, Greenaway J, Le Jeune I, Darwent M, Church N, Reckless I, Hodge R, Dyer C, Meredith S, Llewelyn C, Palmer KR, Logan RF, Travis SP, Walsh TS, Murphy MF. Restrictive versus liberal blood transfusion for acute upper gastrointestinal bleeding (TRIGGER): a pragmatic, open-label, cluster randomised feasibility trial. Lancet. 2015 Jul 11;386(9989):137-44. doi: 10.1016/S0140-6736(14)61999-1. Epub 2015 May 5.
- Campbell HE, Stokes EA, Bargo D, Logan RF, Mora A, Hodge R, Gray A, James MW, Stanley AJ, Everett SM, Bailey AA, Dallal H, Greenaway J, Dyer C, Llewelyn C, Walsh TS, Travis SP, Murphy MF, Jairath V; TRIGGER investigators. Costs and quality of life associated with acute upper gastrointestinal bleeding in the UK: cohort analysis of patients in a cluster randomised trial. BMJ Open. 2015 Apr 29;5(4):e007230. doi: 10.1136/bmjopen-2014-007230.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2012
Primary Completion (Actual)
April 1, 2013
Study Completion (Actual)
August 1, 2013
Study Registration Dates
First Submitted
July 24, 2012
First Submitted That Met QC Criteria
April 2, 2014
First Posted (Estimate)
April 7, 2014
Study Record Updates
Last Update Posted (Estimate)
April 7, 2014
Last Update Submitted That Met QC Criteria
April 2, 2014
Last Verified
April 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 10-09-CSU
- ID 12078 (Other Identifier: NIHR)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gastrointestinal Hemorrhage
-
CURE Digestive Diseases Research CenterUniversity of California, Los Angeles; VA Greater Los Angeles Healthcare SystemRecruitingUpper Gastrointestinal HemorrhageUnited States
-
Odense University HospitalCompleted
-
McMaster UniversityNational Health and Medical Research Council, Australia; Canadian Institutes... and other collaboratorsCompletedGastrointestinal Hemorrhage (Clinically Important, Upper)Canada, Australia, United States, Brazil, Kuwait, Pakistan, Saudi Arabia, United Kingdom
-
Fundació Institut de Recerca de l'Hospital de la...UnknownAcute Upper Gastrointestinal HemorrhageSpain
-
West China HospitalNot yet recruitingUpper Gastrointestinal Hemorrhage
-
Medtronic - MITGCompletedUpper Gastrointestinal HemorrhageHong Kong, Israel
-
Kliniken Ludwigsburg-Bietigheim gGmbHUniversity Hospital, Essen; University of Leipzig; University Hospital Tuebingen and other collaboratorsUnknownAcute Upper Gastrointestinal HemorrhageGermany
-
Seoul National University HospitalUnknownAcute Upper Gastrointestinal HemorrhageKorea, Republic of
-
Kliniken Ludwigsburg-Bietigheim gGmbHUniversity of Zurich; University Hospital Tuebingen; Klinikum Garmisch-Patenkirchen and other collaboratorsUnknownAcute Upper Gastrointestinal HemorrhageGermany
-
The First Affiliated Hospital of Nanchang UniversityCompletedAcute Upper Gastrointestinal Non Variceal Hemorrhage
Clinical Trials on Restrictive transfusion policy
-
University of EdinburghNHS Lothian; Chief Scientist Office of the Scottish Government; Transfusion Medicine...CompletedAnemia | Blood Transfusion | Intensive CareUnited Kingdom
-
Assistance Publique - Hôpitaux de ParisCompletedMyocardial Infarction | Anemia | Blood TransfusionSpain, France
-
Guangdong Provincial People's HospitalNot yet recruitingValve Heart Disease | Cardiac Surgery With Cardiopulmonary BypassChina
-
Unity Health TorontoRecruitingCardiac Surgery | Heart | Postoperative | DisorderCanada, Russian Federation
-
University of Sao PauloCompleted
-
Instituto do CoracaoUnknown
-
Aretaieion University HospitalCompletedSurgery | Cytokine Storm | Infection After Transfusion | Transfusion-related Immunomodulation ReactionGreece
-
Nadine ShehataCanadian Institutes of Health Research (CIHR); Health CanadaCompleted
-
Erasme University HospitalEuropean Society of Intensive Care MedicineCompletedBlood Transfusion | Acute Brain InjuryBelgium
-
Unity Health TorontoCompletedDisorder; Heart, Functional, Postoperative, Cardiac SurgeryCanada, Spain, United States, Israel, Australia, New Zealand, Denmark, Colombia, Egypt, Germany, Singapore, Switzerland, China, Brazil, Greece, India, Malaysia, Romania, South Africa